LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Bespak – 21.05.2025
Stoelzle – 15th May 2025

GSK shares promising results from shingles vaccine trial

The varicella-zoster virus that causes shingles and chicken pox is typically present in over 90% of adults globally.

GSK has announced positive results from its first efficacy trial for Shingrix recombinant zoster vaccine (RZV) in China.

The results follow a post-license phase 4 trial (ZOSTER-076) from GSK, which evaluated the vaccine’s efficacy in preventing shingles in 6,000 individuals over the age of 50.

Those who received the Shingrix vaccination reported no cases, whereas the ones who were given the placebo reported 31 cases.

GSK also carried out the phase 3 trials ZOE-50 and ZOE-70, which demonstrated how the RZV vaccine’s efficacy was up to 97% over the length of four years.

RZV was originally used in 2019 for the prevention of herpes zoster in patients aged over 50, and trials were consequently put in place for the treatment of shingles after its success – the current trials further demonstrate the vaccine’s efficacy for preventing herpes, regardless of sex, ethnicity or geographical region.

The varicella-zoster virus (VZV) that causes shingles and chicken pox is typically present in over 90% of adults globally; it remains in the nervous system until it attempts to reactivate as shingles as age increases.

As the population in China increases, the six million cases of shingles annually are also expected to increase, making this a rising issue for people over the age of 65.

The results from the phase 4 trial will be published later this year in a peer-reviewed scientific journal, GSK said.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025